| Ident. | Authors (with country if any) | Title |
|---|
| 000144 |
R. Carron [France] ; S. Chabardes [France] ; C. Hammond [France] | Les mécanismes d'action de la stimulation cérébrale à haute fréquence. Revue de la littérature et concepts actuels |
| 000282 |
R. Bordet [France] | Bases pharmacologiques des effets disease modifier dans la maladie de Parkinson : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ? |
| 000436 |
Christiane Mendre [France] ; Bernard Mouillac [France] | Chaperons pharmacologiques: Un espoir thérapeutique pour les pathologies conformationnelles |
| 000592 |
S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France] | Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide |
| 000605 |
Feras Hatahet [Finlande] ; Lloyd W. Ruddock [Finlande] | Modulating Proteostasis: Peptidomimetic Inhibitors and Activators of Protein Folding |
| 000613 |
Jean-Francois Desaphy [Italie] ; Antonella Dipalma [Italie] ; Michela De Bellis [Italie] ; Teresa Costanza [Italie] ; Christelle Gaudioso [France] ; Patrick Delmas [France] ; Alfred L. Jr George [États-Unis] ; Diana Conte Camerino [Italie] | Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine |
| 000647 |
Laetitia Monv [France] ; James Nc Kew [Royaume-Uni] ; Martin J. Gunthorpe [Royaume-Uni] ; Pierre Paoletti [France] | Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential |
| 000676 |
P. Martin [France] | Rôle des systèmes mélatoninergiques dans les états dépressifs : aspects pharmacologiques et physiopathologiques |
| 000751 |
Constance Hammond [France] ; Rachida Amman [France] ; Bernard Bioulac [France] ; Liliana Garcia [France] | Latest View on the Mechanism of Action of Deep Brain Stimulation |
| 000753 |
C. Cavin [Suisse] ; M. Marin-Kuan [Suisse] ; S. Langouët [France] ; C. Bezencon [Suisse] ; G. Guignard [Suisse] ; C. Verguet [Suisse] ; D. Piguet [Suisse] ; D. Holzh User [Suisse] ; R. Cornaz [Suisse] ; B. Schilter [Suisse] | Induction of Nrf2-mediated cellular defenses and alteration of phase I activities as mechanisms of chemoprotective effects of coffee in the liver |
| 000926 |
A. Favier [France] | Stress oxydant stress oxydant et pathologies humaines |
| 000945 |
L. Mallet [France] | La stimulation cérébrale profonde : un outil pour la modulation thérapeutique du comportement et des émotions |
| 000962 |
J. Yelnik [France] | Anatomie structurale et fonctionnelle des ganglions de la base |
| 000982 |
Rosa Planells-Cases [Espagne] ; Juan Lerma [Espagne] ; Antonio Ferrer-Montiel [Espagne] | Pharmacological intervention at ionotropic glutamate receptor complexes |
| 000A57 |
France Haour [France] | Mécanismes de l'effet placebo et du conditionnement : Données neurobiologiques chez l'homme et l'animal |
| 000B07 |
D. Guilloteau [France] ; S. Chalon [France] | PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders : Capabilities of PET and SPECT in pre-clinical and clinical research |
| 000B11 |
Marina Mapelli [Italie] ; Lucia Massimiliano [Italie] ; Claudia Crovace [Italie, États-Unis] ; Markus A. Seeliger [États-Unis] ; Li-Huei Tsai [France] ; Laurent Meijer [France] ; Andrea Musacchio [Italie] | Mechanism of CDK5/p25 binding by CDK inhibitors |
| 000B57 |
Alim-Louis Benabid [France] ; Bradley Wallace [France] ; John Mitrofanis [France] ; Rong Xia [France] ; Brigitte Piallat [France] ; Stephan Chabardes [France] ; Francois Berger [France] | A putative generalized model of the effects and mechanism of action of High Frequency Electrical Stimulation of the Central Nervous System |
| 000B96 |
Cameron C. Mcintyre [États-Unis] ; Marc Savasta [France] ; Lydia Kerkerian-Le Goff [France] ; Jerrold L. Vitek [États-Unis] | Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both |
| 000C11 |
Roberto Coccurello [France] ; Nathalie Breysse [France] ; Marianne Amalric [France] | Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats |
| 000C92 |
A. Destee [France] | Neuroprotection et syndromes parkinsoniens neurodégénératifs |
| 000D34 |
Valérie Cochen [France] ; Maria-Joao Ribeiro [France] ; Jean-Paul Nguyen [France] ; Jean-Marc Gurruchaga [France] ; Gabriel Villafane [France] ; Christian Loc'H [France] ; Gilles Defer [France] ; Yves Samson [France] ; Marc Peschanski [France] ; Philippe Hantraye [France] ; Pierre Cesaro [France] ; Philippe Remy [France] | Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue |
| 000E23 |
J.-L. Houeto [France] ; I. Arnulf [France] | Troubles psychiques et somnolence |
| 000E28 |
A. Destee [France] ; R. Bordet [France] | Stimulation dopaminergique continue, stimulation dopaminergique pulsatile |
| 000E30 |
Anne-Marie Bonnet [France] | Récepteurs α2-adrénergiques et maladie de Parkinson |
| 000E38 |
Nathalie Lambeng [France] ; Raphaël Hourez [Belgique] ; Sakina Torch [France] ; Jean-Marc Verna [France] ; David Blum [Belgique] | Mort neuronale dans les modèles expérimentaux de la maladie de Parkinson |
| 000E47 |
Ph. Damier [France] | Les fluctuations |
| 000E51 |
André Galinowski [France] ; Marie-Laure Paillere-Martinot [France] | La stimulation magnétique transcrânienne répétée : Vers un nouvel outil thérapeutique en psychiatrie : Les avancées scientifiques en psychiatrie |
| 000E64 |
P. Derkinderen [France] ; M. Vidailhet [France] | Dyskinésies provoquées par la L-DOPA |
| 000E87 |
Jean Dessolin [France] ; Marie Schuler [France] ; Alice Quinart [France] ; Francesca De Giorgi [France] ; Leon Ghosez [France] ; Francois Ichas [France] | Selective targeting of synthetic antioxidants to mitochondria: towards a mitochondrial medicine for neurodegenerative diseases? |
| 000F13 |
Wakako Maruyama [Japon] ; Yukihiro Akao [Japon] ; Maria Chrisina Carrillo [Argentine] ; Ken-Ichi Kitani [Japon] ; Moussa B. H. Youdium [Israël] ; Makoto Naoi [Japon] | Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of prosurvival genes |
| 000F21 |
Jonathan O. Dostrovsky [Canada] ; Andres M. Lozano [Canada] | Mechanisms of deep brain stimulation |
| 000F22 |
Jerrold L. Vitek [États-Unis] | Mechanisms of deep brain stimulation: Excitation or inhibition |
| 000F24 |
Samuel G. Speciale [États-Unis] | MPTP: Insights into parkinsonian neurodegeneration |
| 000F51 |
Diego Centonze [Italie] ; Alessandro Usiello [France] ; Paolo Gubellini [Italie] ; Antonio Pisani [Italie] ; Emiliana Borrelli [France] ; Giorgio Bernardi [Italie] ; Paolo Calabresi [Italie] | Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors |
| 000F56 |
Yoshimi Misu [Japon] ; Nobuya Furukawa [Japon] ; Nobutaka Arai [Japon] ; Takeaki Miyamae [Japon] ; Yoshio Goshima [Japon] ; Kiyohide Fujita [Japon] | DOPA causes glutamate release and delayed neuron death by brain ischemia in rats |
| 000F63 |
C. Lebrun-Frenay [France] ; M. Borg [France] | Choosing the right dopamine agonist for patients with Parkinson's disease |
| 000F73 |
A. Nicotra [Italie] ; S. H. Parvez [France] | Apoptotic molecules and MPTP-induced cell death |
| 001025 |
Philippe Damier [France] ; Jean-Luc Houeto [France] ; Boulos-Paul Bejjani [Liban] ; Isabelle Arnulf [France] ; Anne-Marie Bonnet [France] ; Malika Miloudy [France] ; Yves Agid [France] | The role of the pallidum in Parkinson's disease: Gait lessons from pallidal stimulation |
| 001032 |
Oum-Kaltoum Hassani [France] ; Mireille Mouroux [France] ; Georg Andrees Bohme [France] ; Jean-Marie Stutzmann [France] ; Jean Feger [France] | Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain |
| 001146 |
Bertrand Bloch [France] | La dopamine dans tous ses états |
| 001175 |
A. Boireau [France] ; P. Dubedat [France] ; F. Bordier [France] ; A. Imperato [France] ; S. Moussaoui [France] | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation |
| 001197 |
Abdelhamid Benazzouz [France] ; Mark Hallett [États-Unis] | Mechanism of action of deep brain stimulation |
| 001237 |
A. Nicotra [Italie] ; S. H. Parvez [France] | Cell death induced by MPTP, a substrate for monoamine oxidase B |
| 001241 |
Makoto Naoi [Japon] ; Wakako Maruyama [Japon] ; Yukihito Akao [Japon] ; JIN ZHANG [Japon] ; Hasan Parvez [France] | Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons |
| 001258 |
| CONTRIBUTION A L'ETUDE DES VARIATIONS PHYSIOLOGIQUES ET PATHOLOGIQUES DES PRESSIONS URETRALES CHEZ L'ANIMAL ET CHEZ L'HOMME |
| 001284 |
E. Broussolle [France] | Arguments en faveur du traitement initial de la maladie de Parkinson par la L-dopa |
| 001345 |
E. Bezard [France] ; C. Brefel [France] ; F. Tison [France] ; H. Peyro-Saint-Paul [France] ; P. Ladure [France] ; O. Rascol [France] ; C. E. Gross [France] | Effect of the α2 adrenoreceptor antagonist, idazoxan, on motor disabilities in mptp-treated monkey |
| 001407 |
C. Brefel-Courbon [France] ; C. Thalamas [France] ; H. Peyro Saint Paul [France] ; J.-M. Senard [France] ; J.-L. Montastruc [France] ; O. Rascol [France] | α2-Adrenoceptor antagonists: A new approach to Parkinson's disease? |
| 001428 |
A. Boireau [France] ; M. Meunier [France] ; A. Imperato [France] | Ouabain-induced increase in dopamine release from mouse striatal slices is antagonized by riluzole |
| 001433 |
E. X. Albuquerque [États-Unis, Brésil] ; E. F. R. Pereira [États-Unis] ; M. F. M. Braga [États-Unis, Brésil] ; H. Matsubayashi [États-Unis] ; M. Alkondon [États-Unis] | Neuronal nicotinic receptors modulate synaptic function in the hippocampus and are sensitive to blockade by the convulsant strychnine and by the anti-Parkinson drug amantadine |
| 001451 |
M. Gentil [France] ; C.-L. Tournier [France] ; S. Perrin [France] ; P. Pollak [France] | Effects of levodopa on finger and orofacial movements in Parkinson's disease |
| 001499 |
| Pallidotomie |
| 001559 |
B. Bejjani [France] ; P. Damier [France] ; I. Arnulf [France] ; A. M. Bonnet [France] ; M. Vidailhet [France] ; D. Dormont [France] ; B. Pidoux [France] ; P. Cornu [France] ; C. Marsault [France] ; Yves Agid [France] | Pallidal stimulation for Parkinson's disease : Two targets? |
| 001566 |
F. Huguet [France] ; G. Page [France] ; P. Morel [France] ; C. Tallineau [France] ; A. Piriou [France] | MPTP toxicity in rat striatal slices : dopamine uptake alteration does not appear to be related to lipid peroxidation |
| 001779 |
H. Loo [France] ; W. De Carvalho ; F. Hartmann ; I. Amado-Boccara | Actualités sur l'électroconvulsivothérapie |
| 001791 |
O. Rascol [France] ; U. Sabatini [France] ; F. Chollet [France] ; N. Fabre [France] ; J. M. Senard [France] ; J. L. Montastruc [France] ; P. Calsis [France] ; J. P. Marc-Vergnes [France] ; A. Rascol [France] | Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa |
| 001804 |
J. L. Montastruc [France] ; M. E. Llau ; O. Rascol ; J. M. Senard | Drug-induced parkinsonism : a review |
| 001885 |
J. M. Senard [France] ; O. Rascol [France] ; G. Durrieu [France] ; M. A. Tran [France] ; M. Berlan [France] ; A. Rascol ; J. L. Montastruc | Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy |
| 001893 |
J. L. Montastruc [France] ; O. Rascol ; J. M. Senard | Current status of dopamine agonists in Parkinson's disease management |
| 001999 |
U. Sabatini [France] ; O. Rascol ; P. Celsis ; G. Houin ; A. Rascol ; J. P. Marc-Vergnes ; J. L. Montastruc | Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms |
| 001A31 |
H. Allain ; D. Bentueê-Ferrer ; J. L. Merot ; R. Decombe | Pharmacologie des agonistes dopaminergiques |
| 001A35 |
F.-J. Authier | Le Déprényl : nouvelles indications dans la maladie de Parkinson |
| 001A82 |
B. Cura ; M. Valli | Intérêts du modèle au 1 méthyl 4 phényl 1, 2, 3, 6 tétrahydropyridine (MPTP) dans la physiopathologie de la maladie de Parkinson |
| 001B31 |
D. Scherman ; F. Darchen ; C. Desnos ; J. P. Henry | 1-Methyl-4-phenylpyridinium is a substrate of the vesicular monoamine uptake system of chromaffin granules |
| 001B94 |
G. Bartholini | GABA receptor agonists: pharmacological spectrum and therapeutic actions |
